CURE’s rare cancers page is a go-to resource for oncology news and updates in the world of rare cancers Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in rare cancers.
Patients with neuroendocrine tumors have more treatment options than ever before.
April 17th 2024, 3:00pm
A type of therapy that involves “liberating” T cells from a suppressive tumor environment showed promise in the treatment of patients with uveal melanoma.
March 21st 2024, 5:00pm
When life hands you cancer lemons, what flavored lemonade do you make?
March 21st 2024, 3:00pm
One expert explains how caregivers are a vital part of the care team during a clinical trial.
March 20th 2024, 5:00pm
The waiting in between scans heightens my scanxiety, even though I've had no evidence of disease for 2 1/2 years.
March 14th 2024, 9:00pm
Of all the bad whatifs about cancer that creep into my ear, what if I turned them into positive whatifs?
March 6th 2024, 4:00pm
In some patients with rare cancers, certain strains of gut bacteria could boost responses to immunotherapy combinations, researchers established.
March 5th 2024, 10:00pm
Lutathera plus Sandostatin improved progression-free survival in patients with advanced gastric neuroendocrine tumors, research showed.
March 3rd 2024, 6:00pm
After reading about breast cancer and aromatase inhibitors, a light went on for me about my leiomyosarcoma diagnosis.
February 27th 2024, 2:00pm
Patients with locally advanced penile squamous cell carcinoma who responded to neoadjuvant chemotherapy followed by consolidative lymphadenectomy experienced improved long-term survival outcomes.
January 5th 2024, 4:00pm
From Shannen Doherty discussing in-vitro fertilization before breast cancer to "Chickadee" Cardwell's cancer experience to be featured on an upcoming TV series, here's what's happening in the oncology space this week.
Receiving Chemotherapy on My Birthday for Colon Cancer
Attitudes With Latitude About My Cancer
Enhertu Marks First Therapy Approved Across HER2-Positive Solid Tumors
Tecentriq, Cabometyx May Not Improve Survival Over Chemo in NSCLC